Special Issue "Analgesic Phytochemicals and Their Medicinal Potential"

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".

Deadline for manuscript submissions: closed (1 November 2023) | Viewed by 553

Special Issue Editor

College of Pharmacy, Federal University of Bahia, Rua Barão de Jeremoabo 147, Salvador 40170-115, Bahia, Brazil
Interests: pain; analgesic; anti-inflammatory; pharmacology; mechanisms of chronic pain
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Pain is a global health problem in modern society. It has been estimated that 1 in 5 adults suffer from pain in the world. Regardless of the amount of clinically available analgesic drugs, there is still a gap in the therapeutic management of pain, as even the most widely used analgesics are still ineffective or unsafe for some patients, especially those suffering from chronic pain. Natural products have been used for healing purposes since the dawn of mankind. Knowledge about medicinal plants has evolved over the centuries, now allowing for the industrial-scale production of plant-derived drugs. Historically, phytochemicals have contributed significantly to the discovery of new analgesics, as illustrated by opioids and non-steroidal anti-inflammatory drugs, which are the basic pharmacological classes for current pain management and were developed from plant-derived compounds. In this context, the special issue "Analgesic Phytochemicals and their Medicinal Potential" invites researchers to contribute original research articles and review articles related to plant-derived analgesic compounds with potential for the drug discovery process. Topics of interest include the pharmacological characterization of phytochemicals in experimental models of pain, studies of mechanism of action, pharmacokinetic profile, adverse effects and toxicity, isolation and identification of new analgesic phytochemicals, pharmaceutical technology of analgesic phytochemicals, and clinical trials.

Prof. Dr. Cristiane Flora Villarreal
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • analgesic
  • pharmacology
  • phytochemistry
  • mechanism of action
  • natural products
  • medicinal plants
  • phytotherapy
  • bioactive molecules
  • pharmaceutical formulations

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 3778 KiB  
Article
Cleomin Exerts Acute Antinociceptive Effects in Mice via GABAB and Muscarinic Receptors
Pharmaceuticals 2023, 16(11), 1547; https://doi.org/10.3390/ph16111547 - 02 Nov 2023
Viewed by 362
Abstract
Cleomin, a 1,3-oxazolidine-2-thione, was recently isolated from Neocalyptrocalyx longifolium, a species traditionally used for treating painful conditions. Reports about the pharmacological activities of cleomin are lacking. Here, the antinociceptive effects of cleomin were investigated using mice models of pain, namely the formalin, [...] Read more.
Cleomin, a 1,3-oxazolidine-2-thione, was recently isolated from Neocalyptrocalyx longifolium, a species traditionally used for treating painful conditions. Reports about the pharmacological activities of cleomin are lacking. Here, the antinociceptive effects of cleomin were investigated using mice models of pain, namely the formalin, the cold plate, and the tail flick tests. Motor integrity was assessed in the rota-rod test. Antagonism assays and in silico docking analyses were performed to investigate the putative mechanisms of action. Cleomin (12.5–25 mg/kg), at doses that did not induce motor impairment, induced dose-dependent antinociception in both early and late phases of the formalin test and reduced nociceptive behaviors in both the cold plate and tail flick tests. Pretreatments with phaclofen and atropine attenuated the antinociceptive effects of cleomin, implicating the involvement of GABAB and muscarinic receptors. In silico docking studies suggested satisfactory coupling between cleomin and GABAB and M2 receptors, hence corroborating their role in cleomin’s activity. Pretreatments with naloxone, yohimbine, bicuculline, and methysergide did not affect the antinociception of cleomin. In silico pharmacokinetics prediction showed a good drug ability profile of cleomin. In conclusion, cleomin promoted antinociception mediated by GABAB and muscarinic receptors. These findings support further investigation of the analgesic potential of cleomin. Full article
(This article belongs to the Special Issue Analgesic Phytochemicals and Their Medicinal Potential)
Show Figures

Figure 1

Back to TopTop